0 results

    Omthera Pharmaceuticals

    Omthera Pharmaceuticals, an emerging specialty pharmaceuticals company focusing on the clinical development of new therapies for dyslipidemia, was purchased by AstraZeneca in 2013.

    • Sector

      Biopharmaceuticals

    • Strategy

      Capital

    • Status

      Exit

    SofinnovaCapital

    The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

    SofinnovaMD Start

    The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

    SofinnovaCrossover

    The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

    SofinnovaIndustrial Biotech

    Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

    SofinnovaTelethon

    The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

    SofinnovaDigital Medicine

    The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

    SofinnovaBiovelocita

    The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.